Results 181 to 190 of about 43,721 (231)

Immunomodulatory effect of Cannabis root extract on inflammatory cascades via endocannabinoid system regulation. [PDF]

BMC Complement Med Ther
Jin HL, Yu GR, Jung H, Lee MS, Kim H, Lim DW, Park WH.   +6 more
europepmc   +1 more source

What Do Thirty Years of Neuroimaging Research Tell Us About Recreational Cannabis Use and Brain Integrity? A Narrative Review of the Multimodal Neuroimaging Evidence to Date. [PDF]

Subst Abuse Rehabil
Murphy E, Suo C, Poudel G, Thomson H, Lorenzetti V.   +4 more
europepmc   +1 more source

Role of Concentration in Opposing Effects of Anandamide on Nociceptive Synapses versus Non-nociceptive Synapses. [PDF]

eNeuro
Burrell BD.
europepmc   +1 more source

Targeting CB1 and TRPM8 receptors to counteract CD8+ T cell exhaustion. [PDF]

Sci Rep
Mohammadzadeh A, Moazzendizzaji S, Mohammadi AT, Ahmadi A, Mahmodlou R, Pourfathollah AA.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pharmacology of cannabinoid CB1 and CB2 receptors.

Pharmacology & Therapeutics, 1997
There are at least two types of cannabinoid receptors, CB1 and CB2, both coupled to G-proteins. CB1 receptors are present in the central nervous system and CB1 and CB2 receptors in certain peripheral tissues. The existence of endogenous cannabinoid receptor agonists has also been demonstrated.
R. Pertwee
semanticscholar   +3 more sources

Involvement of CB1 cannabinoid receptors in emotional behaviour

Psychopharmacology, 2002
Endogenous and exogenous cannabinoids acting through the CB1 cannabinoid receptors are implicated in the control of a variety of behavioural and neuroendocrine functions, including emotional responses, and learning and memory processes. Recently, knockout mice deficient in the CB1 cannabinoid receptor have been generated, and these animals result in an
Marc Parmentier, Martin M, Maldonado R   +2 more
exaly   +4 more sources

The Cannabinoid CB1 Receptor in Schizophrenia

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021
Converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may be involved in the pathophysiology of schizophrenia and suggest that the cannabinoid CB1 receptor may be a potential therapeutic target.
Faith Borgan, Michelle Kokkinou, Oliver Howes   +2 more
openaire   +3 more sources